Efficacy of topical cyclosporine 0.5% in vernal keratoconjuctivitis.

Abstract

Objective: To evaluate the effectiveness of Topical cyclosporine 0.05% in comparison to topical artificial tear formulation (Tear Natural II) in the treatment of severe VKC. Study Design: Randomized Controlled Trial. Setting: Ziauddin University Hospital. Period: July 1 2022, to June 30, 2023. Methods: A group of individuals presented at the eye outpatient ophthalmology department (OPD) with complaints of redness, itching and watery discharges underwent clinical examination and were diagnosed with VKC based on inclusion criteria. Data was collected and analyzed using SPSS 23, with the Chi square test employed for variable comparisons. Result: In this study of 92 diagnosed VKC cases, participants were divided into two groups: Group 1 (interventional) and Group 2 (control), consisting of 47 and 38 individuals, respectively, with an average age of 9.6±2.3 years. Among them, 64 were boys (75.3%), and 21 were girls (24.7%). Group 1 showed improvement with a majority experiencing mild or quiescent symptoms, while Group 2 demonstrated worsening conditions, with a substantial portion reaching severe or very severe stages during the final follow-up assessment after six months. Conclusion: In conclusion, our research highlights the effectiveness of the topical cyclosporine o.o5% in significantly improving the condition of VKC patients over a six-month period.